Top Inhaler Brands: Finding Your Breath of Fresh Air

In recent years, the demand for high-quality inhalers has surged, with various brands emerging as top contenders in the market. Individuals seeking effective solutions for respiratory conditions have a range of options from renowned manufacturers who prioritize both innovation and user comfort. Not only do these brands offer reliable performance, but they also provide varying designs to cater to specific patient needs, ensuring accessibility for everyone. For those interested in discovering the leading names in the inhaler industry, take a look below to find out more.

Illustration of inhaler

Best brands of inhaler in 2025

Ventolin

Ventolin, a leading brand in the inhaler market, holds a significant market share of approximately 55% for salbutamol inhalers, despite being partially funded and incurring an additional patient charge of around $4 per inhaler. In the 2014/2015 financial year, an estimated 970,000 Ventolin inhalers were dispensed in New Zealand, indicating its widespread use. Ventolin HFA is a prescription inhaled medicine used to treat or prevent bronchospasm in people with reversible obstructive airway disease and to prevent exercise-induced bronchospasm. It is available in 2 sizes (200 sprays or 60 sprays) and features a built-in dose counter. The brand's popularity is evident from its high dispensing rates, with 52% of prescribers writing more than 50% of their prescriptions for Ventolin.

ProAir

ProAir, a renowned brand in the respiratory inhaler market, is known for its high-quality and effective respiratory inhalers, such as ProAir HFA (albuterol sulfate) inhalation aerosol, which is a short-acting beta agonist used for quick relief in patients with reversible obstructive airway disease and exercise-induced bronchospasm. The FDA approved the first generic version of ProAir HFA in 2020 to enhance patient access to lower-cost medicines, highlighting the brand's commitment to affordability and accessibility. Despite Teva discontinuing the manufacturing of ProAir HFA in 2022, an authorized generic option remains available, ensuring continued patient access. ProAir HFA is part of the broader respiratory inhalers market, which is projected to grow at a CAGR of 5.7% from 2022 to 2028, reaching $43.44 billion by 2028. The brand's products are integral to managing respiratory conditions, such as asthma and COPD, affecting millions of people globally.

Symbicort

Symbicort, developed by AstraZeneca, is a leading inhaler brand in the respiratory market, particularly for treating asthma and chronic obstructive pulmonary disease (COPD). It combines the inhaled corticosteroid budesonide and the long-acting beta-agonist formoterol, effectively addressing both airway inflammation and bronchoconstriction. In 2004, Symbicort held a 27% market share in the combination asthma market in five major European markets, with projections to increase to 38% by 2008. In the U.S., Symbicort Turbohaler generated $1.24 billion in revenue in 2016, positioning it among the top respiratory products. Its innovative dosing strategies, such as the SMART regimen, have been key factors in its market success. For more detailed information on their respiratory treatments, visit AstraZeneca's respiratory focus page.

Advair

Advair, a flagship product of GlaxoSmithKline, has revolutionized the treatment of asthma and chronic obstructive pulmonary disease (COPD) with its innovative combination of fluticasone propionate and salmeterol xinafoate. Launched in April 2001, Advair quickly gained blockbuster status, accounting for about 10% of all weekly prescriptions for respiratory controller medications in the U.S. within just four months. By 2005, global sales of Advair were forecasted to reach $2.4 billion, solidifying its position as a gold standard in asthma care. The product's ease of use and clinical efficacy have made it a preferred choice, with studies showing it significantly improves lung function and reduces asthma symptoms. Available in 38 countries under various trade names, Advair continues to be a leading treatment option. For more detailed information, visit their official Advair website.

Spiriva

Spiriva, developed by Boehringer Ingelheim, is a leading brand in the respiratory therapy market, particularly for the treatment of chronic obstructive pulmonary disease (COPD) and asthma. It generated significant revenue, with $1.87 billion in the U.S. in 2016, making it one of the top respiratory products globally. Spiriva Respimat, a key product, improves breathing by relaxing the air passages and is used once daily, with each cartridge providing 60 puffs or 30 doses. The global market for asthma and COPD therapeutics, in which Spiriva is a major player, is expected to grow at a CAGR of 7.3% to reach $44.1 billion by 2031. Spiriva's effectiveness in reducing COPD exacerbations and its long-term maintenance treatment make it a crucial medication in respiratory care.

Trelegy

Trelegy Ellipta, developed by GSK, is a leading single inhaler triple therapy (SITT) treatment for COPD and asthma, boasting strong growth globally with a 27% increase in sales in 2023 and a 29% growth in Q4 2023. It is the most prescribed SITT treatment worldwide, with asthma accounting for over 40% of its sales by 2022. The medication combines fluticasone furoate, umeclidinium, and vilanterol, making it a once-daily treatment that stands out in its class. Trelegy's success is further highlighted by its dominance in the respiratory market, contributing significantly to the growth of the global asthma therapeutics market.

Breo

BREO Ellipta, produced by GlaxoSmithKline, is a leading brand in the inhaler market, particularly for treating chronic obstructive pulmonary disease (COPD) and asthma. The global BREO Ellipta drugs market is expected to grow at a CAGR of 4.53% from 2023 to 2030, reaching a market size of USD 4.16 billion by 2030. This growth is driven by the increasing prevalence of respiratory diseases and advancements in drug delivery systems. BREO Ellipta combines an inhaled corticosteroid (fluticasone furoate) and a long-acting beta2-adrenergic agonist (vilanterol), providing 24 hours of symptom control. The market is dominated by North America, with significant contributions from Europe and emerging markets in Asia-Pacific and Latin America. For more information about BREO Ellipta, visit their official website.

Flovent

Flovent, a brand by GlaxoSmithKline (GSK), was a leading producer of inhalers, particularly the Flovent HFA and Flovent Diskus, which were widely used for long-term control of asthma. However, GSK discontinued these products as of December 31, 2023, with supplies expected to be depleted by early 2024. Despite this, authorized generic versions of these inhalers will remain available. Flovent HFA was a metered dose inhaler containing fluticasone propionate, a common inhaled corticosteroid. The discontinuation reflects a broader shift in pharmaceutical marketing efforts towards treating more severe asthma cases. For more information, visit the Asthma and Allergy Foundation of America.

Dulera

Dulera, a brand-name prescription medication, is a leading producer of inhalers, particularly for treating asthma in adults and children aged 5 years and older. It contains the active ingredients mometasone, an inhaled corticosteroid, and formoterol, a long-acting beta agonist (LABA), which help reduce swelling in the lungs and relax airway muscles. Clinical studies have shown that Dulera increases the forced expiratory volume (FEV1) by an average of 0.13 L, and it is available in three strengths with either 60 or 120 puffs per canister. Dulera is administered twice a day and has been proven effective, with asthma worsening in only 30% of patients compared to 56% on a placebo. It is not currently available in generic form, ensuring its brand integrity and effectiveness. For more detailed information, you can refer to the Dulera Product Information.

Xopenex

Xopenex, a brand of levalbuterol, is a leading producer of inhalers, particularly effective in treating reversible obstructive airway diseases such as asthma, bronchitis, and emphysema. It works as a bronchodilator, opening airways to ease breathing, and is often used as a rescue or quick-relief inhaler. Each Xopenex HFA inhaler delivers 59 mcg of levalbuterol tartrate per actuation, with each canister containing 200 metered actuations. The medication is available in various strengths and is administered via nebulization or metered-dose inhaler. Xopenex is widely used, reflecting the growing demand for effective respiratory treatments, especially with the increasing prevalence of asthma affecting around 235 million people globally each year. For more detailed information, visit their official drug page.